Atopic Dermatitis: Systemic Immunosuppressive Therapy

Seminars in Cutaneous Medicine and Surgery

Volumn 27, Issue 2, 2008, Pages 151-155

  Akhavan, Arash ^a   Rudikoff, Donald ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; EFALIZUMAB; GAMMA INTERFERON; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PIMECROLIMUS; PLACEBO; RITUXIMAB; TACROLIMUS;

ARTICLE; ATOPIC DERMATITIS; BONE MARROW SUPPRESSION; BONE NECROSIS; CATARACT; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CUSHING DISEASE; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; FEVER; FLU LIKE SYNDROME; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLAUCOMA; GLUCOSE INTOLERANCE; GROWTH RETARDATION; HEADACHE; HERPES; HERPES RETINITIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOMA; MACULOPAPULAR RASH; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; MYOPATHY; NAUSEA; NEPHRITIS; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OSTEOLYSIS; PHOTOTHERAPY; PNEUMONIA; RETINITIS; RISK FACTOR; SIDE EFFECT; SKIN CANCER; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; URTICARIA; VASCULITIS; VOMITING;

DERMATITIS, ATOPIC; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME;

EID: 46649117668     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2008.04.004     Document Type: Article

References (44)

1. Lipozencic J., and Wolf R. Atopic dermatitis: An update and review of the literature. Dermatol Clin 25 (2007) 605-612
2. Hong J., Koo B., and Koo J. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther 21 (2008) 54-59
3. Gottlieb A.B. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol 53 suppl 1 (2005) S3-S16
4. Sonenthal K.R., Grammer L.C., and Patterson R. Do some patients with atopic dermatitis require long-term oral steroid therapy?. J Allergy Clin Immunol 91 (1993) 971-973
5. Forte W.C., Sumita J.M., Rodrigues A.G., et al. Rebound phenomenon to systemic corticosteroid in atopic dermatitis. Allergol Immunopathol (Madr) 33 (2005) 307-311
6. Schmitt J., Schakel K., Schmitt N., and Meurer M. Systemic treatment of severe atopic eczema: A systematic review. Acta Derm Venereol 87 (2007) 100-111
7. Zonneveld I.M., De Rie M.A., Beljaards R.C., et al. The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: A comparison of two dosage regimens. Br J Dermatol 135 suppl 48 (1996) 15-20
8. van Joost T., Heule F., Korstanje M., et al. Cyclosporin in atopic dermatitis: A multicentre placebo-controlled study. Br J Dermatol 130 (1994) 634-640
9. Sowden J.M., Berth-Jones J., Ross J.S., et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 338 (1991) 137-140
10. Berth-Jones J., Graham-Brown R.A., Marks R., et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 136 (1997) 76-81
11. Hoare C., Li Wan Po A., and Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 4 (2000) 1-191
12. Madan V., and Griffiths C.E. Systemic cyclosporin and tacrolimus in dermatology. Dermatol Ther 20 (2007) 239-250
13. Pedreira C.C., King E., Jones G., et al. Oral cyclosporin plus topical corticosteroid therapy diminishes bone mass in children with eczema. Pediatr Dermatol 24 (2007) 613-620
14. Wolff K., Fleming C., Hanifin J., et al. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: A randomized controlled trial. Br J Dermatol 152 (2005) 1296-1303
15. Lear J.T., English J.S., Jones P., et al. Retrospective review of the use of azathioprine in severe atopic dermatitis. J Am Acad Dermatol 35 (1996) 642-643
16. Kuanprasert N., Herbert O., and Barnetson R.S. Clinical improvement and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine. Australas J Dermatol 43 (2002) 125-127
17. Berth-Jones J., Takwale A., Tan E., et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 147 (2002) 324-330
18. Meggitt S.J., and Reynolds N.J. Azathioprine for atopic dermatitis. Clin Exp Dermatol 26 (2001) 369-375
19. Dicarlo J.B., and McCall C.O. Pharmacologic alternatives for severe atopic dermatitis. Int J Dermatol 40 (2001) 82-88
20. Murphy L.A., and Atherton D.J. Azathioprine as a treatment for severe atopic eczema in children with a partial thiopurine methyl transferase (TPMT) deficiency. Pediatr Dermatol 20 (2003) 531-534
21. Knowles S.R., Gupta A.K., Shear N.H., et al. Azathioprine hypersensitivity-like reactions-a case report and a review of the literature. Clin Exp Dermatol 20 (1995) 353-356
22. Neuber K., Schwartz I., Itschert G., et al. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 143 (2000) 385-391
23. Grundmann-Kollmann M., Podda M., Ochsendorf F., et al. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 137 (2001) 870-873
24. Murray M.L., and Cohen J.B. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 32 (2007) 23-27
25. Heller M., Shin H.T., Orlow S.J., and Schaffer J.V. Mycophenolate mofetil for severe childhood atopic dermatitis: Experience in 14 patients. Br J Dermatol 157 (2007) 127-132
26. Dasgupta N., Gelber A.C., Racke F., et al. Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis. Lupus 14 (2005) 910-913
27. Vernino S., Salomao D.R., Habermann T.M., et al. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 65 (2005) 639-641
28. Communication About an Ongoing Safety Review of CellCept (mycophenolate mofetil) and Myfortic (mycophenolate acid) (2008), US Food and Drug Administration; Center for Drug Evaluation and Research
29. Egan C.A., Rallis T.M., Meadows K.P., et al. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol 40 (1999) 612-614
30. Shaffrali F.C., Colver G.B., Messenger A.G., et al. Experience with low-dose methotrexate for the treatment of eczema in the elderly. J Am Acad Dermatol 48 (2003) 417-419
31. Weatherhead S.C., Wahie S., Reynolds N.J., et al. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol 156 (2007) 346-351
32. Bateman E.A., Ardern-Jones M., and Ogg G.S. Dose-related reduction in allergen-specific T cells associates with clinical response of atopic dermatitis to methotrexate. Br J Dermatol 156 (2007) 1376-1377
33. Musial J., Milewski M., Undas A., et al. Interferon-gamma in the treatment of atopic dermatitis: influence on T-cell activation. Allergy 50 (1995) 520-523
34. Hanifin J.M., Schneider L.C., Leung D.Y., et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 28 (1993) 189-197
35. Jang I.G., Yang J.K., Lee H.J., et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 42 (2000) 1033-1040
36. Jacobi A., Antoni C., Manger B., et al. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 52 (2005) 522-526
37. Chacko M., and Weinberg J.M. Efalizumab Dermatol Ther 20 (2007) 265-269
38. Takiguchi R., Tofte S., Simpson B., et al. Efalizumab for severe atopic dermatitis: A pilot study in adults. J Am Acad Dermatol 56 (2007) 222-227
39. Harper E.G., Simpson E.L., Takiguchi R.H., et al. Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen. J Invest Dermatol 128 (2008) 1173-1181
40. Forman S.B., and Garrett A.B. Success of omalizumab as monotherapy in adult atopic dermatitis: Case report and discussion of the high-affinity immunoglobulin E receptor. FcepsilonRI: Cutis 80 (2007) 38-40
41. Belloni B., Ziai M., Lim A., et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 120 (2007) 1223-1225
42. Simon D., Hosli S., Kostylina G., et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 121 (2008) 122-128
43. Sediva A., Kayserova J., Vernerova E., et al. Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol (2008)
44. Buys L.M. Treatment options for atopic dermatitis. Am Fam Physician 75 (2007) 523-528